Attempts to curb surprise medical may still result in patients getting costs elsewhere, said Bret Jackson, president of the Economic Alliance for Michigan.
Attempts to curb surprise medical may still result in patients getting costs elsewhere, said Bret Jackson, president of the Economic Alliance for Michigan.
What is your view on the bill in Congress to reduce healthcare costs and how it approaches surprise medical billing?
So, the debate in Washington is whether or not we’re going to have a Medicare-plus rate to reimburse on surprise bills, or are we going to go into arbitration. And, I think what arbitration does is really codify the practice of surprise billing, which is a way around provider agreements. Instead of patients being able to really see relief, while the bill may relieve the patients upfront, they’re going to get the [charges] in added premiums, increased deductibles, increased co-pays; so, ultimately, a patient is going to pay for a surprise bill.
We would rather see Congress act on policies that allow for a long-term, stable arrangement between providers and insurance companies, rather than have a system where an arbitrator picks one price versus the other.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More